Is a dose adjustment of venlafaxine (Effexor) necessary in a patient taking 75mg of venlafaxine when initiating terbinafine (Lamisil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dose Adjustment of Venlafaxine When Starting Terbinafine

Yes, you should strongly consider reducing the venlafaxine dose or closely monitoring for adverse effects when initiating terbinafine, as terbinafine is a potent CYP2D6 inhibitor that can increase venlafaxine levels nearly 5-fold. 1

Mechanism of Drug Interaction

  • Terbinafine potently inhibits CYP2D6, the primary enzyme responsible for converting venlafaxine to its active metabolite O-desmethylvenlafaxine (ODV). 1
  • In a controlled pharmacokinetic study, terbinafine increased venlafaxine plasma concentrations to 490% of baseline (nearly 5-fold increase) while simultaneously decreasing ODV levels to 57% of baseline. 1
  • The ratio of active metabolite to parent drug decreased by 82%, fundamentally altering the pharmacologic profile of venlafaxine. 1

Clinical Significance at 75mg Venlafaxine

  • At your current dose of 75mg daily, the effective exposure could increase to approximately 367mg equivalent based on the 490% AUC increase documented in research. 1
  • This magnitude of increase substantially exceeds the typical therapeutic range and approaches the maximum recommended dose of 225mg/d for venlafaxine. 2
  • Venlafaxine requires caution in patients with cardiac disease due to potential blood pressure increases and cardiac conduction abnormalities, risks that would be amplified by this interaction. 2

Duration of Interaction

  • This interaction persists for months after stopping terbinafine, not just during active treatment. 3
  • A case report documented that serum concentrations of tricyclic antidepressants (which share CYP2D6 metabolism with venlafaxine) remained elevated for approximately 6 months after discontinuing terbinafine. 3
  • Terbinafine has highly variable elimination half-lives ranging from 17-400 hours, making the interaction duration unpredictable. 3

Recommended Management Strategy

Option 1 (Preferred): Dose Reduction

  • Reduce venlafaxine to 37.5mg daily when initiating terbinafine, which would result in effective exposure similar to your current 75mg dose. 1
  • Monitor for loss of antidepressant efficacy during the first 2-4 weeks. 2

Option 2: Enhanced Monitoring Without Dose Change

  • Monitor closely for venlafaxine toxicity including excessive sedation, nausea, dizziness, hypertension, and cardiac symptoms. 2, 1
  • Check blood pressure regularly, as venlafaxine can cause dose-dependent hypertension that would be exacerbated by this interaction. 2
  • Be prepared to reduce the dose if adverse effects emerge.

Option 3: Alternative Antifungal

  • Consider an alternative to terbinafine if the indication allows (e.g., topical therapy with amorolfine or ciclopirox for onychomycosis). 4, 5
  • Voriconazole causes only a minor 31% increase in venlafaxine exposure and may be safer, though it has its own side effect profile. 1

Critical Monitoring Parameters

  • Cardiovascular monitoring: Blood pressure checks weekly for the first month, as both medications can affect blood pressure. 2
  • Neuropsychiatric symptoms: Increased sedation, dizziness, anxiety, or serotonergic symptoms. 2
  • Gastrointestinal effects: Nausea and vomiting, which are common with both medications and may be additive. 2, 4

Common Pitfall to Avoid

  • Do not assume the interaction resolves immediately after stopping terbinafine. The inhibitory effect on CYP2D6 can persist for 3-6 months, requiring continued monitoring and potential dose adjustments during this extended period. 3, 6
  • If you discontinue terbinafine while maintaining the reduced venlafaxine dose, you may need to increase venlafaxine back to baseline over several months as the interaction gradually resolves. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Terbinafine Safety Profile

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Terbinafine Use in Onychomycosis with Mild ALT Elevation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Terbinafine : Relevant drug interactions and their management].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.